Biogen pauses or cancels most R&D programs from its $5.6B Apellis buyout and lays off staff, keeping its focus on Empaveli and Syfovre.
June 25, 2026 08:50 PM EDT
DealsR&D
After buying Apellis for $5.6B, Biogen is cutting most of its pipeline work
Kyle LaHucik
Biotech Correspondent
AbbVie to buy Apogee Therapeutics in nearly $11B deal
Another big deal, another sign biotech M&A is back
AbbVie’s Costly Apogee Acquisition Has Long-Term Upside: Analyst - AbbVie (NYSE:ABBV), Apogee Therapeutic
AbbVie Goes On The Offensive With $10.9 Billion Takeover
AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs
Zymeworks acquires struggling Theravance for $929M
AbbVie's Big Immunology Acquisition
AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition - AbbVie (NYSE:ABBV), Apogee Ther
AbbVie compra la 'biotech' Apogee por 10.900 millones de d�lares
Pharma: AbbVie schluckt Biotechfirma Apogee für 10,9 Milliarden Dollar
